Latest news with #YoungLi
Yahoo
11-07-2025
- Business
- Yahoo
Jefferies Maintains Buy Rating on Accuray Stock, Keeps PT at $4.5
Accuray Incorporated (NASDAQ:ARAY) is one of the . On June 9, Jefferies maintained a Buy rating on Accuray, with a price target of $4.5. Young Li from Jefferies maintained a Buy rating on the stock, citing the company's strategic initiatives and market positioning. Li remains positive about the way Accuray is handling tariff challenges and commends its strong foundation in the Chinese market. Li cited its recent exchange of convertible notes as a catalyst for its financial position. On June 6, the company entered into a new senior secured credit agreement, removing its 'financial overhang' and improving its financial flexibility. A researcher in a lab coat analyzing the effects of PD-L1 on GITR Expressing Cells to advance the targeted oncology. After achieving a 12% year-over-year revenue growth in Q3 FY2025, Accuray expects revenue in the range of $121 million to $129 million. Whereas, the adjusted EBITDA is projected to be in the range of $9.5 million to $12 million. Both revenue and EBITDA guidance are well ahead of the results in Q3, indicating robust growth in both developed and emerging markets. Accuray Incorporated (NASDAQ:ARAY) offers unique radiation treatments to meet patient needs. The company is focused on developing innovative solutions for oncology and neuro-radiosurgery. While we acknowledge the potential of ARAY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
26-06-2025
- Business
- Yahoo
Jefferies Maintains a Buy on Enovis (ENOV), Sets a $60 PT
Enovis Corporation (NYSE:ENOV) is one of the 13 Small Cap Stocks Analysts Are Bullish On. On May 28, Jefferies analyst Young Li maintained a Buy rating on Enovis Corporation (NYSE:ENOV) and set a price target of $60.00. The positive rating was based on several key factors, as the company reported a strong start to the year with notable growth figures in fiscal Q1 2025. A patient recieving cold therapy treatment using the company's products. Its net sales for the quarter grew 8% on a reported basis compared to the same quarter in 2024, while adjusted EBITDA reached $99 million, or 17.7% of sales. This translates to a 160 basis points growth compared to last year. The analyst attributed the growth to the company's successful commercial execution and integration efforts, as well as additional potential from cross-selling opportunities and new product launches. Enovis Corporation (NYSE:ENOV) is also increasing its free cash flow conversion and expanding margins, which positions it well for future profitability. The analyst further reasoned that the company has an attractive valuation and is trading below its peers, which points toward the potential for multiple expansions. Enovis Corporation (NYSE:ENOV) is a medical technology growth company that develops clinically differentiated solutions to transform workflows and generate better patient outcomes. The company operates through the Prevention & Recovery and Reconstructive segments. While we acknowledge the potential of ENOV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
24-06-2025
- Business
- Yahoo
Jefferies Maintains a Buy on Enovis (ENOV), Sets a $60 PT
Enovis Corporation (NYSE:ENOV) is one of the 13 Small Cap Stocks Analysts Are Bullish On. On May 28, Jefferies analyst Young Li maintained a Buy rating on Enovis Corporation (NYSE:ENOV) and set a price target of $60.00. The positive rating was based on several key factors, as the company reported a strong start to the year with notable growth figures in fiscal Q1 2025. A patient recieving cold therapy treatment using the company's products. Its net sales for the quarter grew 8% on a reported basis compared to the same quarter in 2024, while adjusted EBITDA reached $99 million, or 17.7% of sales. This translates to a 160 basis points growth compared to last year. The analyst attributed the growth to the company's successful commercial execution and integration efforts, as well as additional potential from cross-selling opportunities and new product launches. Enovis Corporation (NYSE:ENOV) is also increasing its free cash flow conversion and expanding margins, which positions it well for future profitability. The analyst further reasoned that the company has an attractive valuation and is trading below its peers, which points toward the potential for multiple expansions. Enovis Corporation (NYSE:ENOV) is a medical technology growth company that develops clinically differentiated solutions to transform workflows and generate better patient outcomes. The company operates through the Prevention & Recovery and Reconstructive segments. While we acknowledge the potential of ENOV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
